Arcus Capital Partners LLC Has $699,000 Stake in Danaher Co. (NYSE:DHR)

Arcus Capital Partners LLC trimmed its holdings in Danaher Co. (NYSE:DHR) by 11.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,800 shares of the conglomerate’s stock after selling 358 shares during the period. Arcus Capital Partners LLC’s holdings in Danaher were worth $699,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC raised its holdings in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Van ECK Associates Corp raised its stake in Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after purchasing an additional 916,513 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC raised its stake in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. raised its stake in Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE:DHR opened at $203.56 on Friday. The firm has a market cap of $147.03 billion, a PE ratio of 38.55, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The firm’s fifty day moving average is $230.49 and its 200-day moving average is $250.28. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm posted $2.09 EPS. Sell-side analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.53%. Danaher’s payout ratio is 20.45%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several analyst reports. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research report on Friday, December 13th. Guggenheim began coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. Barclays lowered their price objective on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.